Aura Biosciences, Inc. Operating Lease, Payments
Aura Biosciences, Inc. (AURA) reported Operating Lease, Payments of $1.68 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-08-11
- Aura Biosciences, Inc. operating lease, payments for the quarter ending 2026-06-30 was $841.00K, a 2.94% increase year-over-year.
- Aura Biosciences, Inc. operating lease, payments for the quarter ending 2026-03-31 was $841.00K, a 3.06% increase year-over-year.
- Aura Biosciences, Inc. operating lease, payments for the quarter ending 2025-12-31 was $841.00K, a 2.94% increase year-over-year.
- Aura Biosciences, Inc. operating lease, payments for the quarter ending 2025-09-30 was $832.00K, a 98.10% increase year-over-year.
- Aura Biosciences, Inc. operating lease, payments for fiscal 2025 was $3.31M, a 17.15% increase from fiscal 2024.
- Aura Biosciences, Inc. operating lease, payments for fiscal 2024 was $2.82M, a 6.00% decline from fiscal 2023.
- Aura Biosciences, Inc. operating lease, payments for fiscal 2023 was $3.00M, a 77.63% increase from fiscal 2022.
- Aura Biosciences, Inc. operating lease, payments for fiscal 2022 was $1.69M, a 225.63% increase from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $841.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $1.68M 10-Q · filed 2026-08-11 | $2.52M derived: sum of 3 quarters · filed 2026-08-11 | $3.35M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $841.00K 10-Q · filed 2026-05-11 | $1.68M derived: sum of 2 quarters · filed 2026-05-11 | $2.51M derived: sum of 3 quarters · filed 2026-05-11 | $3.33M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $841.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $1.67M derived: sum of 2 quarters · filed 2026-03-30 | $2.49M derived: sum of 3 quarters · filed 2026-08-11 | $3.31M 10-K · filed 2026-03-30 |
| 2025-09-30 | $832.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $1.65M derived: sum of 2 quarters · filed 2026-08-11 | $2.46M 10-Q · filed 2025-11-13 | $3.28M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $817.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $1.63M 10-Q · filed 2026-08-11 | $2.45M derived: sum of 3 quarters · filed 2026-08-11 | $2.87M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $816.00K 10-Q · filed 2026-05-11 | $1.63M derived: sum of 2 quarters · filed 2026-05-11 | $2.05M derived: sum of 3 quarters · filed 2026-05-11 | $2.89M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $817.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $1.24M derived: sum of 2 quarters · filed 2026-03-30 | $2.07M derived: sum of 3 quarters · filed 2026-03-30 | $2.82M 10-K · filed 2026-03-30 |
| 2024-09-30 | $420.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $1.25M derived: sum of 2 quarters · filed 2025-11-13 | $2.00M 10-Q · filed 2025-11-13 | $2.80M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $834.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $1.58M 10-Q · filed 2025-08-13 | $2.38M derived: sum of 3 quarters · filed 2025-08-13 | $3.05M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $751.00K 10-Q · filed 2025-05-15 | $1.54M derived: sum of 2 quarters · filed 2025-05-15 | $2.22M derived: sum of 3 quarters · filed 2025-05-15 | $2.98M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $793.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $1.47M derived: sum of 2 quarters · filed 2025-03-24 | $2.23M derived: sum of 3 quarters · filed 2025-03-24 | $3.00M 10-K · filed 2025-03-24 |
| 2023-09-30 | $672.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $1.44M derived: sum of 2 quarters · filed 2024-11-12 | $2.21M 10-Q · filed 2024-11-12 | $2.98M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $769.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.54M 10-Q · filed 2024-08-08 | $2.31M derived: sum of 3 quarters · filed 2024-08-08 | $2.92M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $768.00K 10-Q · filed 2024-05-09 | $1.54M derived: sum of 2 quarters · filed 2024-05-09 | $2.15M derived: sum of 3 quarters · filed 2024-05-09 | $2.31M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $768.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $1.39M derived: sum of 2 quarters · filed 2024-03-27 | $1.54M derived: sum of 3 quarters · filed 2024-03-27 | $1.69M 10-K · filed 2024-03-27 |
| 2022-09-30 | $617.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $769.00K derived: sum of 2 quarters · filed 2023-11-09 | $922.00K 10-Q · filed 2023-11-09 | $1.07M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $152.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $305.00K 10-Q · filed 2023-08-09 | $457.00K derived: sum of 3 quarters · filed 2023-08-09 | $610.00K derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $153.00K 10-Q · filed 2023-05-11 | $305.00K derived: sum of 2 quarters · filed 2023-05-11 | $458.00K derived: sum of 3 quarters · filed 2023-05-11 | $584.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $152.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $305.00K derived: sum of 2 quarters · filed 2023-03-15 | $431.00K derived: sum of 3 quarters · filed 2023-03-15 | $519.00K 10-K · filed 2023-03-15 |
| 2021-09-30 | $153.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $279.00K derived: sum of 2 quarters · filed 2022-11-10 | $367.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $126.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $214.00K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $88.00K 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |